Advancements in HR+/HER2- aBC Management

Integrity CE
A

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & Fulvestrant for Aromatase Inhibitor-Resistant HR+/HER2- Advanced BC"

By Integrity CE FEATURING Aditya Bardia
By Integrity CE FEATURING Aditya Bardia
1,557 views
January 26, 2024
Comments 3
Login to view comments. Click here to Login
10:04

The Importance of Molecular Testing in HR+/HER2- mBC

UNC Lineberger Comprehensive Cancer Center

Y. Abdou

383 views
09:17

Advanced HR+ BC: Elacestrant vs. ET, Alpelisib/Inavolisib for PIK3CA…

UChicago Medicine

N. Chen

234 views
14:09

Overcoming Endocrine Resistance in HR+/HER2- mBC

Parvin Peddi

343 views
08:48

2L Therapy for ER+ mBC Following CDK4/6i

James Martin

578 views
04:18

SABCS 2023 Insights: "Comparison of NGS Results From the Cerebrospin…

Insights from 2023 SABCS

L. Huppert

264 views
08:24

SABCS 2023 Insights: "PROs From the CAPItello-291 Trial Investigatin…

Insights from 2023 SABCS

H. Rugo

610 views
21:37

Standard Treatments for HR+/HER2- mBC in 2023

Dana-Farber Cancer Institute

S. Sammons

919 views
21:44

Updates on Metastatic Breast Cancer - Yale Cancer Center

Yale Cancer Center

D. O'Neil

568 views